A follow up on the feasibility after national implementation of magnesium sulfate for neuroprotection prior to preterm birth
Open Access
- 8 September 2023
- journal article
- research article
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 102 (12) , 1741-1748
Abstract
Introduction: The risk for brain injury manifested as cerebral palsy is higher in very preterm born children than in term. Prenatal administration of magnesium sulfate (MgSO4) has been shown to be neuroprotective and reduces the proportion of very preterm born children later diagnosed with cerebral palsy. A Swedish national clinical practice guideline was implemented in March 2020, stipulating the administration of a single intravenous dose of 6 g MgSO4 1–24 h prior to delivery before gestational age 32+0, aiming for 90% treatment coverage. The aim of this study was to evaluate the feasibility of this new clinical practice guideline in the first year of its implementation.Material and methods: Data on MgSO4 treatment were collected by reviewing the medical charts of women who gave birth to live born children in gestational age 22+0–31+6 during the period of March 1, 2020 to February 28, 2021, at five Swedish university hospitals. Women with pre‐eclampsia, eclampsia, or high elevated liver enzymes low platelets (HELLP) were excluded.Results: A total of 388 women were eligible and 79% received treatment with MgSO4. Of the 21% not receiving treatment, 9% did not receive treatment due to lack of knowledge about the clinical practice guideline, 9% were not possible to treat and 3% had missing data. The proportion treated increased from 72% to 87% from the first to the last 3 months. Of those treated, 81% received the drug within the stipulated timeframe (mean 8.7 h, median 3.4 h).Conclusions: There was a positive trend over time in the proportion of women receiving MgSO4 treatment, but the a priori target of 90% was not reached during the first year of implementation. Our findings indicate that this target could be reached with additional information to clinicians.Keywords
Funding Information
- Stiftelsen Mary von Sydows, född Wijk, donationsfond
- Stiftelserna Wilhelm och Martina Lundgrens (2019‐2941)
- Vetenskapsrådet (2019‐01320 (HH))
This publication has 26 references indexed in Scilit:
- An update on the prevalence of cerebral palsy: a systematic review and meta‐analysisDevelopmental Medicine & Child Neurology, 2013
- Feasibility of implementing magnesium sulphate for neuroprotection in a tertiary obstetric unitAustralian and New Zealand Journal of Obstetrics and Gynaecology, 2012
- A Randomized, Controlled Trial of Magnesium Sulfate for the Prevention of Cerebral PalsyNew England Journal of Medicine, 2008
- Do clinical guidelines enhance safe practice in obstetrics and gynaecology?Best Practice & Research Clinical Obstetrics & Gynaecology, 2007
- Gross and fine motor function and accompanying impairments in cerebral palsyDevelopmental Medicine & Child Neurology, 2007
- Extremely preterm cesarean delivery: a clinical studyActa Obstetricia et Gynecologica Scandinavica, 2006
- The Magpie Trial: a randomised trial comparing magnesium sulphate with placebo for pre‐eclampsia. Outcome for women at 2 yearsBJOG: An International Journal of Obstetrics & Gynaecology, 2006
- Magnesium sulphate given before very‐preterm birth to protect infant brain: the randomised controlled PREMAG trial*BJOG: An International Journal of Obstetrics & Gynaecology, 2006
- Gross and fine motor function and accompanying impairments in cerebral palsyDevelopmental Medicine & Child Neurology, 2006
- Effect of Magnesium Sulfate Given for Neuroprotection Before Preterm BirthA Randomized Controlled TrialJAMA, 2003